Gabapentin Capsule
Product Images NDC 68788-8194

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (F396ec70 826d 45c6 A27c 343c2fac878c 00)

Label for Gabapentin Capsules 100 mg (CV), generic for Neurontin, manufactured by ACI Healthcare USA, Inc. The label includes storage instructions, manufacturer information, and dosage directions in English and Spanish. The capsule description notes it is white and imprinted with AHD 100. The labeler is Preferred Pharmaceuticals Inc.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration depicting the formula to calculate creatinine clearance (CLCr), which incorporates age, weight, serum creatinine levels, and a factor adjustment for female patients. This calculation is relevant to dosage considerations for Gabapentin capsules.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring attached to a central carbon bonded to an amino (CH2NH2) group and a carboxylic acid (CH2CO2H) group.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over 8 weeks between placebo and gabapentin 3600 mg/day groups. The horizontal axis marks weeks, including baseline and a 4-week dose titration followed by a 4-week fixed dose period. The vertical axis shows mean pain score from 0 to 10. Gabapentin shows a decreasing trend, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period, including a 3-week dose titration and 4-week fixed dose. It compares placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, with pain scores decreasing over time for both Gabapentin doses relative to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. It compares placebo (PBO) responses (12% and 14%) with Gabapentin (GBP) at 3600 mg (29%), 1800 mg (32%), and 2400 mg (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

This is a scatter plot depicting the percent difference in response related to daily dose (mg) for Gabapentin capsules. The chart compares data points from three studies labeled Study A, Study B, and Study C, with daily doses ranging from about 600 mg to 1800 mg and percent differences ranging approximately from 2% to over 17%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.